Technical Analysis for AVTE - Aerovate Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 26.39 | -1.16% | -0.31 |
AVTE closed down 1.16 percent on Monday, March 18, 2024, on 1.9 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Mar 27
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
180 Bullish Setup | Bullish Swing Setup | -1.16% | |
Stochastic Reached Overbought | Strength | -1.16% | |
Wide Bands | Range Expansion | -1.16% | |
Overbought Stochastic | Strength | -1.16% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 8.65% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 8.65% | |
Inside Day | Range Contraction | 8.65% |
Alert | Time |
---|---|
Possible NR7 | about 19 hours ago |
Possible Inside Day | about 19 hours ago |
2x Volume Pace | about 22 hours ago |
1.5x Volume Pace | about 23 hours ago |
Down 5% | about 23 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/27/2024
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Chemical Compounds Hypertension Orphan Drug Pulmonary Arterial Hypertension Pulmonary Hypertension Imatinib Piperazines
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Chemical Compounds Hypertension Orphan Drug Pulmonary Arterial Hypertension Pulmonary Hypertension Imatinib Piperazines
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 27.82 |
52 Week Low | 9.41 |
Average Volume | 100,741 |
200-Day Moving Average | 16.77 |
50-Day Moving Average | 21.09 |
20-Day Moving Average | 23.20 |
10-Day Moving Average | 25.09 |
Average True Range | 2.34 |
RSI (14) | 60.16 |
ADX | 33.38 |
+DI | 25.25 |
-DI | 7.77 |
Chandelier Exit (Long, 3 ATRs) | 20.80 |
Chandelier Exit (Short, 3 ATRs) | 25.06 |
Upper Bollinger Bands | 28.33 |
Lower Bollinger Band | 18.07 |
Percent B (%b) | 0.81 |
BandWidth | 44.26 |
MACD Line | 1.57 |
MACD Signal Line | 1.34 |
MACD Histogram | 0.2325 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 29.21 | ||||
Resistance 3 (R3) | 29.14 | 28.13 | 28.74 | ||
Resistance 2 (R2) | 28.13 | 27.41 | 28.16 | 28.58 | |
Resistance 1 (R1) | 27.26 | 26.96 | 26.75 | 27.33 | 28.43 |
Pivot Point | 26.25 | 26.25 | 25.99 | 26.28 | 26.25 |
Support 1 (S1) | 25.38 | 25.53 | 24.87 | 25.45 | 24.35 |
Support 2 (S2) | 24.37 | 25.08 | 24.40 | 24.20 | |
Support 3 (S3) | 23.50 | 24.37 | 24.04 | ||
Support 4 (S4) | 23.57 |